Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-10-04 Regulatory Filings
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from BioVie Inc. to the SEC responding to comments on an Amendment No. 4 to a Registration Statement on Form S-1. It discusses disclosures related to capital stock and warrants in the offering. The document is short (1624 characters) and is clearly a correspondence related to a regulatory filing, specifically a registration statement amendment. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a regulatory correspondence related to securities registration. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2019-10-04 English
FORM S-1 AMENDMENT NO. 5
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A (Amendment No. 5) filed with the U.S. Securities and Exchange Commission, which is a registration statement under the Securities Act of 1933. It is used by companies planning an initial public offering (IPO) or other securities offering to register their securities with the SEC. The text includes detailed information about the offering, company background, risk factors, use of proceeds, management, and financial statements index. This is not an annual report, earnings release, or any other financial report type but a registration statement for a securities offering. According to the filing definitions, this corresponds to a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2019-10-04 English
Regulatory Filings 2019
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. The text does not contain any officer certifications or attestations. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The confidence is moderate due to the inability to extract meaningful content but the clear absence of any other identifiable filing type.
2019-10-03 English
8-A12B/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-A/A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It describes the registration of Class A common stock and warrants for BioVie Inc. There are no financial statements or performance data included, and the document is primarily a regulatory filing for securities registration. It is not an annual report, earnings release, or any other financial report type. Given the nature and content, this fits best under Regulatory Filings (RNS). The document length is 3835 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2019-10-02 English
FORM S-1 AMENDMENT NO.4
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Amendment No. 4 filed with the U.S. Securities and Exchange Commission, which is a registration statement under the Securities Act of 1933. It is related to the registration of securities for a public offering by BioVie Inc. The text includes details about the offering, underwriting, risk factors, business description, management, and financial statements index. This type of filing is a capital raising document used for initial or follow-on public offerings, not an annual report, earnings release, or other report types. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing rather than a brief announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2019-10-02 English
FORM 10-K FOR PERIOD ENDING JUNE 30, 2019
Annual Report FY 2019
2019-09-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.